Key Drivers
- Cash Cushion
- Deep Losses
- Negative FCF
AIAI Summary
RLAY has shifted from a cash-burning biotech to a late-stage oncology catalyst story with real clinical validation (breakthrough designation, Phase 3 move, early responses), but the investable question is now whether that science can outrun ongoing dilution, heavy burn, and execution risk to justify the recent rerating.
Price Chart
Financial Metrics
Deep Analysis
Research tool. Not personalized advice.
Fundamental Analysis
Key Financial Insights:
- •Cash Cushion
- •Deep Losses
- •Negative FCF
RLAY has a very strong cash-rich balance sheet and low debt, but persistent losses, weak cash generation, and poor operating efficiency keep the investment case risky.
Price Behavior
Key Price Behavior Insights:
- •Higher highs
- •Breakout support
- •Resistance stall
RLAY has turned into a bullish but extended short-term uptrend over the last month, holding its prior breakout zone as support while stalling at nearby resistance and needing a clean break above the recent high to confirm more upside.
Sharp pullback on 2026-07-01 after a failed push above resistance
Sentiment & News
Key News Insights:
- •Conference Spotlight
- •Insider Selling
- •Stock Rally
Relay Therapeutics gained visibility from a Goldman Sachs conference presentation, while a later sizable insider sale by Thomas Catinazzo trimmed his stake amid a year-long 500% stock rally.
The news is broadly neutral, but the large insider sale may temper sentiment despite continued investor engagement and strong recent share performance
Similar Companies in Healthcare
Other companies in the same sector with AI ratings